Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study calls for mass screening of Lynch Syndrome

This article was originally published in Clinica

Executive Summary

A US study has recommended that colon cancer patients should be tested for Lynch Syndrome, a hereditary condition which carries an extremely high risk for cancer. The study, published in the New England Journal of Medicine (May 5), showed that at least 23 out of 1,066 patients (2.2%) with recently-diagnosed adenocarcinoma of the colorectum and who underwent DNA microsatellite-instability testing and immunochemistry staining were found to have a Lynch Syndrome-associated deleterious mutation.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT055095

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel